Published in Nature on September 06, 2012
Improved targeting of JAK2 leads to increased therapeutic efficacy in myeloproliferative neoplasms. Blood (2014) 1.68
Molecular pathways: Jak/STAT pathway: mutations, inhibitors, and resistance. Clin Cancer Res (2013) 1.59
CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative Neoplasms. Cancer Cell (2015) 1.24
Activity of the Type II JAK2 Inhibitor CHZ868 in B Cell Acute Lymphoblastic Leukemia. Cancer Cell (2015) 1.10
Targeting JAK kinase in solid tumors: emerging opportunities and challenges. Oncogene (2015) 1.03
Molecular pathways: molecular basis for sensitivity and resistance to JAK kinase inhibitors. Clin Cancer Res (2014) 0.99
Co-targeting the PI3K/mTOR and JAK2 signalling pathways produces synergistic activity against myeloproliferative neoplasms. J Cell Mol Med (2013) 0.99
AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer. Sci Transl Med (2015) 0.98
BET protein inhibition shows efficacy against JAK2V617F-driven neoplasms. Leukemia (2013) 0.97
RAS signaling promotes resistance to JAK inhibitors by suppressing BAD-mediated apoptosis. Sci Signal (2014) 0.96
The molecular regulation of Janus kinase (JAK) activation. Biochem J (2014) 0.95
Acylglycerol kinase augments JAK2/STAT3 signaling in esophageal squamous cells. J Clin Invest (2013) 0.94
Targeting novel signaling pathways for resistant acute myeloid leukemia. Mol Genet Metab (2014) 0.94
Combined targeting of JAK2 and Bcl-2/Bcl-xL to cure mutant JAK2-driven malignancies and overcome acquired resistance to JAK2 inhibitors. Cell Rep (2013) 0.91
Advances in myelofibrosis: a clinical case approach. Haematologica (2013) 0.91
Combination treatment for myeloproliferative neoplasms using JAK and pan-class I PI3K inhibitors. J Cell Mol Med (2013) 0.90
A novel STAT inhibitor, OPB-31121, has a significant antitumor effect on leukemia with STAT-addictive oncokinases. Blood Cancer J (2013) 0.87
Systems biology of cancer: entropy, disorder, and selection-driven evolution to independence, invasion and "swarm intelligence". Cancer Metastasis Rev (2013) 0.86
JAK2 activation by growth hormone and other cytokines. Biochem J (2015) 0.85
Therapy with JAK2 inhibitors for myeloproliferative neoplasms. Hematol Oncol Clin North Am (2012) 0.85
A Pilot Study of Quantitative MRI Parametric Response Mapping of Bone Marrow Fat for Treatment Assessment in Myelofibrosis. Tomography (2016) 0.85
Signal transduction in the chronic leukemias: implications for targeted therapies. Curr Hematol Malig Rep (2013) 0.84
Emerging therapeutic paradigms to target the dysregulated Janus kinase/signal transducer and activator of transcription pathway in hematological malignancies. Leuk Lymphoma (2014) 0.84
Mechanistic insights into activation and SOCS3-mediated inhibition of myeloproliferative neoplasm-associated JAK2 mutants from biochemical and structural analyses. Biochem J (2014) 0.83
SIAH2 antagonizes TYK2-STAT3 signaling in lung carcinoma cells. Oncotarget (2014) 0.83
Discovery of a drug targeting microenvironmental support for lymphoma cells by screening using patient-derived xenograft cells. Sci Rep (2015) 0.82
Adaptive Chromatin Remodeling Drives Glioblastoma Stem Cell Plasticity and Drug Tolerance. Cell Stem Cell (2016) 0.82
Establishing the role of tyrosine kinase 2 in cancer. Oncoimmunology (2013) 0.81
Novel myelofibrosis treatment strategies: potential partners for combination therapies. Leukemia (2014) 0.81
Janus kinase inhibitors and allogeneic stem cell transplantation for myelofibrosis. Biol Blood Marrow Transplant (2014) 0.81
JAK kinase targeting in hematologic malignancies: a sinuous pathway from identification of genetic alterations towards clinical indications. Haematologica (2015) 0.81
Evaluation of the in vitro and in vivo efficacy of the JAK inhibitor AZD1480 against JAK-mutated acute lymphoblastic leukemia. Mol Cancer Ther (2014) 0.80
Divergent modulation of Src-family kinase regulatory interactions with ATP-competitive inhibitors. ACS Chem Biol (2014) 0.80
Novel therapies for myelofibrosis. Leuk Lymphoma (2015) 0.79
Intrinsic resistance to JAK2 inhibition in myelofibrosis. Clin Cancer Res (2013) 0.79
Acceleration of Bcr-Abl+ leukemia induced by deletion of JAK2. Leukemia (2014) 0.79
The arrival of JAK inhibitors: advancing the treatment of immune and hematologic disorders. BioDrugs (2013) 0.78
Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias. Blood (2015) 0.77
Efficacy of ruxolitinib for myelofibrosis. Expert Opin Pharmacother (2014) 0.77
Efficacy and safety of ruxolitinib in the treatment of patients with myelofibrosis. Future Oncol (2015) 0.77
Redox regulation of Janus kinase: The elephant in the room. JAKSTAT (2013) 0.77
Contribution of chaperones to STAT pathway signaling. JAKSTAT (2014) 0.76
Mesenchymal Cell Reprogramming in Experimental MPLW515L Mouse Model of Myelofibrosis. PLoS One (2017) 0.76
Therapeutic targeting of IL-7Rα signaling pathways in ALL treatment. Blood (2016) 0.76
Novel insights into the biology and treatment of chronic myeloproliferative neoplasms. Leuk Lymphoma (2014) 0.76
A method for screening and validation of resistant mutations against kinase inhibitors. J Vis Exp (2014) 0.76
Enu mutagenesis identifies a novel platelet phenotype in a loss-of-function Jak2 allele. PLoS One (2013) 0.76
Clinical potential of pacritinib in the treatment of myelofibrosis. Ther Adv Hematol (2015) 0.75
The photosensitizer verteporfin has light-independent anti-leukemic activity for Ph-positive acute lymphoblastic leukemia and synergistically works with dasatinib. Oncotarget (2016) 0.75
Single agent BMS-911543 Jak2 inhibitor has distinct inhibitory effects on STAT5 signaling in genetically engineered mice with pancreatic cancer. Oncotarget (2015) 0.75
A phase I, open-label, dose-escalation, multicenter study of the JAK2 inhibitor NS-018 in patients with myelofibrosis. Leukemia (2016) 0.75
Mechanisms and consequences of Jak-STAT signaling in the immune system. Nat Immunol (2017) 0.75
Investigational histone deacetylase inhibitors (HDACi) in myeloproliferative neoplasms. Expert Opin Investig Drugs (2016) 0.75
Therapeutics: Holding JAK back. Nat Rev Cancer (2012) 0.75
The PIM inhibitor AZD1208 synergizes with ruxolitinib to induce apoptosis of ruxolitinib sensitive and resistant JAK2-V617F-driven cells and inhibit colony formation of primary MPN cells. Oncotarget (2015) 0.75
Kinase signaling and targeted therapy for primary myelofibrosis. Exp Hematol (2016) 0.75
ALOX5 exhibits anti-tumor and drug-sensitizing effects in MLL-rearranged leukemia. Sci Rep (2017) 0.75
Targeting substrate-site in Jak2 kinase prevents emergence of genetic resistance. Sci Rep (2015) 0.75
New Strategies in Myeloproliferative Neoplasms: The Evolving Genetic and Therapeutic Landscape. Clin Cancer Res (2016) 0.75
BET protein bromodomain inhibitor-based combinations are highly active against post-myeloproliferative neoplasm secondary AML cells. Leukemia (2016) 0.75
Small molecules to the rescue: Inhibition of cytokine signaling in immune-mediated diseases. J Autoimmun (2017) 0.75
JAK2 inhibitors for myeloproliferative neoplasms: what is next? Blood (2017) 0.75
Developmental Therapeutics in Myeloproliferative Neoplasms. Clin Lymphoma Myeloma Leuk (2017) 0.75
Genome-wide maps of chromatin state in pluripotent and lineage-committed cells. Nature (2007) 65.18
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med (2009) 46.35
Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med (2010) 36.57
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science (2007) 32.68
EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med (2005) 26.35
Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med (2005) 25.93
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med (2001) 24.51
A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med (2005) 21.48
Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science (2001) 20.30
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature (2010) 18.69
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet (2005) 18.59
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature (2005) 18.43
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature (2010) 14.62
Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med (2009) 13.47
KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med (2005) 13.40
Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell (2002) 13.03
A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell (2010) 11.20
Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med (2010) 8.77
MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med (2006) 7.95
Jak2 is essential for signaling through a variety of cytokine receptors. Cell (1998) 5.92
Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL. Cell (2003) 5.71
Identification of an acquired JAK2 mutation in polycythemia vera. J Biol Chem (2005) 5.58
JAK mutations in high-risk childhood acute lymphoblastic leukemia. Proc Natl Acad Sci U S A (2009) 4.98
Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J Clin Oncol (2011) 4.06
HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humans. J Clin Invest (2010) 1.93
Identification of potent water soluble purine-scaffold inhibitors of the heat shock protein 90. J Med Chem (2006) 1.88
Jak2: normal function and role in hematopoietic disorders. Curr Opin Genet Dev (2007) 1.69
Efficacy of the JAK2 inhibitor INCB16562 in a murine model of MPLW515L-induced thrombocytosis and myelofibrosis. Blood (2010) 1.42
The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2(V617F). Leukemia (2007) 1.35
Modulation of activation-loop phosphorylation by JAK inhibitors is binding mode dependent. Cancer Discov (2012) 1.25
JAK2 tyrosine kinase phosphorylates PAK1 and regulates PAK1 activity and functions. J Biol Chem (2007) 0.98
Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A (2005) 167.46
MicroRNA expression profiles classify human cancers. Nature (2005) 69.12
Genome-wide maps of chromatin state in pluripotent and lineage-committed cells. Nature (2007) 65.18
Model-based analysis of ChIP-Seq (MACS). Genome Biol (2008) 51.63
Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals. Nature (2009) 35.48
The landscape of somatic copy-number alteration across human cancers. Nature (2010) 31.88
Genome-scale DNA methylation maps of pluripotent and differentiated cells. Nature (2008) 30.29
In vitro reprogramming of fibroblasts into a pluripotent ES-cell-like state. Nature (2007) 28.24
Mapping and analysis of chromatin state dynamics in nine human cell types. Nature (2011) 24.37
Many human large intergenic noncoding RNAs associate with chromatin-modifying complexes and affect gene expression. Proc Natl Acad Sci U S A (2009) 20.66
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell (2005) 17.41
Initial genome sequencing and analysis of multiple myeloma. Nature (2011) 17.28
Dissecting direct reprogramming through integrative genomic analysis. Nature (2008) 16.47
Active genes are tri-methylated at K4 of histone H3. Nature (2002) 15.68
Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell (2010) 15.20
The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell (2010) 13.13
Genomewide analysis of PRC1 and PRC2 occupancy identifies two classes of bivalent domains. PLoS Genet (2008) 11.17
Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med (2012) 10.20
Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med (2011) 9.90
ChIP-seq guidelines and practices of the ENCODE and modENCODE consortia. Genome Res (2012) 9.13
Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med (2010) 8.77
Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell (2006) 8.59
Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer (2006) 8.57
Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood (2006) 8.38
Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood (2006) 8.33
JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med (2007) 8.18
IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature (2012) 7.95
MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med (2006) 7.95
Decrease in anogenital distance among male infants with prenatal phthalate exposure. Environ Health Perspect (2005) 7.43
Charting histone modifications and the functional organization of mammalian genomes. Nat Rev Genet (2010) 7.39
Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer Cell (2011) 7.37
Densely interconnected transcriptional circuits control cell states in human hematopoiesis. Cell (2011) 7.03
Comparison of sequencing-based methods to profile DNA methylation and identification of monoallelic epigenetic modifications. Nat Biotechnol (2010) 7.00
Hepatocytes and epithelial cells of donor origin in recipients of peripheral-blood stem cells. N Engl J Med (2002) 6.33
Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med (2014) 6.12
Unbiased reconstruction of a mammalian transcriptional network mediating pathogen responses. Science (2009) 6.07
MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood (2006) 5.95
Charting a dynamic DNA methylation landscape of the human genome. Nature (2013) 5.80
A novel tumour-suppressor function for the Notch pathway in myeloid leukaemia. Nature (2011) 5.78
Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood (2009) 5.72
Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia. Nature (2010) 5.43
Stem cell gene expression programs influence clinical outcome in human leukemia. Nat Med (2011) 5.24
The role of mutations in epigenetic regulators in myeloid malignancies. Nat Rev Cancer (2012) 4.97
(R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible. Science (2013) 4.88
Signaling network model of chromatin. Cell (2002) 4.87
Jarid2 and PRC2, partners in regulating gene expression. Genes Dev (2010) 4.65
Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain. PLoS Med (2006) 4.63
Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood (2008) 4.61
Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators. Cancer Cell (2006) 4.52
Highly sensitive method for genomewide detection of allelic composition in nonpaired, primary tumor specimens by use of affymetrix single-nucleotide-polymorphism genotyping microarrays. Am J Hum Genet (2007) 4.52
Ribosomopathies: human disorders of ribosome dysfunction. Blood (2010) 4.43
The JAK2/STAT3 signaling pathway is required for growth of CD44⁺CD24⁻ stem cell-like breast cancer cells in human tumors. J Clin Invest (2011) 4.41
Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia. Cancer Cell (2012) 4.41
Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science (2013) 4.39
Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood (2010) 4.33
p53 regulates hematopoietic stem cell quiescence. Cell Stem Cell (2009) 4.30
Cellular and genetic diversity in the progression of in situ human breast carcinomas to an invasive phenotype. J Clin Invest (2010) 4.22
Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate. Clin Cancer Res (2005) 4.00
Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood (2006) 3.88
Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood (2004) 3.84
Pasireotide for postoperative pancreatic fistula. N Engl J Med (2014) 3.84
MicroRNA-mediated control of cell fate in megakaryocyte-erythrocyte progenitors. Dev Cell (2008) 3.84
Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol (2011) 3.83
Genome-wide chromatin state transitions associated with developmental and environmental cues. Cell (2013) 3.83
Locus-specific editing of histone modifications at endogenous enhancers. Nat Biotechnol (2013) 3.82
Akt forms an intracellular complex with heat shock protein 90 (Hsp90) and Cdc37 and is destabilized by inhibitors of Hsp90 function. J Biol Chem (2002) 3.70
L3MBTL1, a histone-methylation-dependent chromatin lock. Cell (2007) 3.70
RAD51 135G-->C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies. Am J Hum Genet (2007) 3.63
Molecular regulation of H3K4 trimethylation by ASH2L, a shared subunit of MLL complexes. Nat Struct Mol Biol (2006) 3.54
Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma. J Clin Oncol (2005) 3.51
Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia. Blood (2006) 3.48
Epigenetic reprogramming in cancer. Science (2013) 3.47
Methylation of histone H3 K4 mediates association of the Isw1p ATPase with chromatin. Mol Cell (2003) 3.47
The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes. Blood (2005) 3.47
Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells. Cancer Cell (2010) 3.46
Defining functional DNA elements in the human genome. Proc Natl Acad Sci U S A (2014) 3.35